|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600126921 |
|
最近更新日期: Date of Last Refreshed on: |
2026-06-18 16:51:39 |
|
注册时间: Date of Registration: |
2026-06-18 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
TMS刺激55b区对卒中后非流利性失语患者语言功能影响及多模态脑成像机制研究 |
|
Public title: |
Study on the Impact of TMS Stimulation of 55b Region on Language Function in Post-stroke Non-fluent Aphasia Patients and the Multimodal Brain Imaging Mechanism |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
TMS刺激55b区对卒中后非流利性失语患者语言功能影响及多模态脑成像机制研究 |
|
Scientific title: |
Study on the Impact of TMS Stimulation of 55b Region on Language Function in Post-stroke Non-fluent Aphasia Patients and the Multimodal Brain Imaging Mechanism |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
单春雷 |
研究负责人: |
单春雷 |
|
Applicant: |
Chunlei Shan |
Study leader: |
Chunlei Shan |
|
申请注册联系人电话: Applicant telephone: |
+86 21 52039999 |
研究负责人电话: Study leader's telephone: |
+86 21 52039999 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
shanclhappy@163.com |
研究负责人电子邮件: Study leader's E-mail: |
shanclhappy@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市长宁区仙霞路1111号 |
研究负责人通讯地址: |
上海市长宁区仙霞路1111号 |
|
Applicant address: |
1111 Xianxia Road, Changning District, Shanghai |
Study leader's address: |
1111 Xianxia Road, Changning District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海交通大学医学院附属同仁医院 |
||
|
Applicant's institution: |
Tongren Hospital affiliated to Shanghai Jiao Tong University School of Medicine |
||
|
研究负责人所在单位: |
上海市同仁医院 |
||
|
Affiliation of the Leader: |
Shanghai Tongren Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
同仁伦审2026-009-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市同仁医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Shanghai Tongren Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-04 00:00:00 |
||
|
伦理委员会联系人: |
王春燕 |
||
|
Contact Name of the ethic committee: |
Wang ChunYan |
||
|
伦理委员会联系地址: |
上海市长宁区仙霞路1111号 |
||
|
Contact Address of the ethic committee: |
1111 Xianxia Road, Changning District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 53039999 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
wongchy@hotmail.com |
|
研究实施负责(组长)单位: |
上海市同仁医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Tongren Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市长宁区仙霞路1111号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1111 Xianxia Road, Changning District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-selected topic (self-financed) |
||||||||||||||||||||||
|
Target disease: |
Post-stroke non-fluent aphasia patients, post-stroke non-aphasia patients |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究旨在针对当前55b区在卒中后失语症研究中面临的核心问题,通过“机制探索-即时干预-长期调控”的三步研究设计,系统揭示55b区在语言加工网络中的作用,评估TMS精准调控55b区的疗效,并阐明其神经重塑机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to address the key issues regarding area 55b in research on post-stroke aphasia. Adopting a three-stage design of **mechanism exploration, immediate intervention and long-term regulation**, it systematically explores the role of area 55b in the language processing network, evaluates the therapeutic efficacy of precise TMS modulation on area 55b, and elucidates the underlying neural remodeling mechanisms. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.健康组: (1)年龄 30-75 岁,性别不限,右利手(利手问卷评分≥80 分); (2)母语为汉语,小学及以上文化程度,能配合完成 MRI 、fNIRS检查; (3)无神经系统疾病、严重心肝肾疾病、精神疾病等; (4)近 3 个月未参加其他神经调控相关研究。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Healthy Group; (1). Aged 30-75, of either gender, right-handed (with a handedness questionnaire score >=80); (2) Native Chinese speaker, with an educational level of primary school or above, and able to cooperate with MRI and fNIRS examinations; (3) Free from neurological disorders, severe heart, liver, and kidney diseases, and mental illnesses; (4) Not involved in other neuroregulation-related studies within the past 3 months. 2. Post-stroke Non-fluent Aphasia Group; (1). Diagnosed with cerebral infarction according to the "Diagnostic Key Points of Various Major Cerebrovascular Diseases in China 2019", confirmed by cranial MRI; (2) Diagnosed with non-fluent aphasia by the Western Aphasia Battery (WAB); (3) Aged 30-75, Han ethnicity, right-handed, native Chinese speaker, with an educational level of primary school or above; (4) Disease duration of 1-12 months, conscious, single and initial occurrence, with the lesion located on the left side; (5) Normal language function before onset, with language dysfunction as the main symptom after onset, and mild limb dysfunction; (6) Able to cooperate with functional magnetic resonance imaging (fMRI) examinations. 3. Post-stroke Non-aphasia Group; (1). Diagnosed with cerebral infarction according to the "Diagnostic Key Points of Various Major Cerebrovascular Diseases in China 2019", confirmed by cranial MRI; (2) Aged 30-75, Han ethnicity, right-handed, native Chinese speaker, with an educational level of primary school or above; (3) Disease duration of 1-12 months, conscious, single and initial occurrence, with the lesion located on the left side; (4) Able to cooperate with fMRI examinations. |
||||||||||||||||||||||
|
排除标准: |
1.听觉障碍(纯音测听阈值>40dB)、智力减退或认知障碍导致无法配合任务; 2.体内有金属植入物(如心脏起搏器、人工耳蜗、脑深部刺激器); 3.妊娠期或哺乳期女性; 4.有癫痫病史或癫痫家族史,或近 1 个月服用抗癫痫药物; 5.严重心、肝、肾功能损伤及昏迷; 6.先天或幼年疾病致学习困难和语言功能缺陷; (7)由于意识障碍和智力减退造成的语言障碍; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Auditory impairment (pure tone audiometric threshold >40dB), intellectual decline, or cognitive impairment resulting in inability to cooperate with tasks; 2. Having metal implants in the body (such as cardiac pacemakers, cochlear implants, and deep brain stimulators); 3. Women who are pregnant or breastfeeding; 4. History of epilepsy or family history of epilepsy, or taking antiepileptic drugs in the past month; 5. Severe impairment of heart, liver, and kidney function, as well as coma; 6. Learning difficulties and language function deficits caused by congenital or childhood diseases; 7. Language barriers caused by consciousness disorders and mental decline; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2028-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-06-22 00:00:00 至 To 2028-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
治疗分配列表由计算机生成的随机数集中产生,随机化序列由专人分层。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The treatment allocation list is generated centrally by computer-generated random numbers, and the randomization sequence is stratified by a designated person. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
三盲(受试者盲、研究者盲、数据分析者盲) |
|
Blinding: |
The triple-blind design includes Blinding of Subjects,Researchers and Data Analysts |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
原始数据经去标识化处理后,在研究成果发表后 6 个月内上传至国家人口健康科学数据中心进行统一归档与受控共享,按照国家健康数据共享管理规定对外开放合规使用。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After de-identification, the raw data shall be uploaded to the National Population and Health Science Data Center within six months following the publication of the research findings for unified archiving and controlled sharing, ensuring compliant access in accordance with national health data sharing regulations. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究采用电子化数据采集系统(EDC)进行前瞻性数据采集,实行权限分级管理、操作留痕、自动逻辑核查;数据录入、修改、核查均有完整日志记录,确保数据真实可溯源。原始数据由专人负责管理,云端加密存储 + 本地定期双备份,完成匿名化脱敏处理,严格遵守数据安全、隐私保护及人类遗传资源管理相关规定。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
This study used an electronic data collection system (EDC) for prospective data collection, implementing hierarchical management of permissions, operation tracking, and automatic logical verification; Complete log records are kept for data entry, modification, and verification to ensure the authenticity and traceability of the data. The raw data is managed by a dedicated person, encrypted and stored in the cloud, and backed up locally on a regular basis. It is anonymized and anonymized, and strictly adheres to relevant regulations on data security, privacy protection, and human genetic resource management. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |